Palantir's 6-Day Freefall: Selloff Ends? A Buy at $150?

Palantir Technologies ( $Palantir Technologies Inc.(PLTR)$ ) has endured a punishing six-day decline, tumbling 18% from its record high of $190.50 on August 12 to $156.18 on August 20, 2025, erasing $73 billion in market value despite a Q2 revenue milestone of $1 billion. This extended slump, the longest since April 2024, has investors questioning if it's a healthy correction or the start of a deeper downturn. With the S&P 500 at 6,466.58, Bitcoin at $115,000, and oil at $75/barrel amid 30-35% tariffs, the tech sector's volatility is amplified. The VIX at 14.49 suggests calm, but Palantir's RSI at 42 hints at oversold conditions. Is this profit-taking after a 93% year-to-date rally, or a bigger correction ahead? Is now a buy-the-dip moment at $150, or too risky with $40 as a fair price? This detailed breakdown explores the drivers, risks, and strategies to navigate Palantir's pivotal moment.

The Freefall Unpacked: What Triggered the Plunge?

Palantir's decline stems from a mix of factors:

Profit-Taking Pressure: After a 93% year-to-date rally to $156.18, investors cashed in, with the stock dropping 18% in six days, erasing $73 billion in value amid broader tech reassessment.
Valuation Concerns: Trading at a forward P/E of 245x, far above the S&P 500's 21.4x, Palantir faces scrutiny from shorts like Citron Research, which targeted $40-$50 based on a comparison to OpenAI’s $500 billion valuation.
Earnings Afterglow Fades: The company’s Q2 report, with $678 million revenue (up 27% YoY) and a $1 billion milestone, initially sparked gains, but slowing U.S. commercial growth (20% vs. 54% in 2024) and a 95% MIT report on zero AI ROI fueled doubts.
Market Rotation: The tech sector dipped 2.4% over five days, while healthcare rose 4%, suggesting a shift from high-growth names like Palantir, with its $148 billion market cap now under pressure.
Technical Warning: The 50-day moving average at $145 and support at $150 are being tested, with resistance at $165; a break below $150 could accelerate losses to $142, per TradingView data.

Posts found on X reflect a divide, with bulls defending Palantir's AI edge and bears echoing Citron's "overvalued" call, suggesting sentiment is at a tipping point.

Market Context: Correction or Consolidation?

The broader landscape adds nuance:

Tech Volatility: The Nasdaq's 21,713.14 peak contrasts with Palantir's slump, as peers like NVIDIA ($141.20, up 28% YTD) and AMD ($174.50, up 22% YTD) hold firm, but a 5-10% sector dip could drag Palantir to $140 if AI skepticism deepens.
Macro Risks: Tariffs and a potential Fed rate cut delay (83% probability for September) could pressure growth stocks, with Prism Capital's 0.9% GDP cut forecast adding to the mix.
Global Cues: U.S. retail sales up 0.3% in July and India's 100 GW solar milestone support tech, but KCB Group's 8% profit rise in Kenya hints at emerging market resilience that Palantir's international revenue (34%) could leverage.
Sentiment Shift: Analyst consensus holds a $134.72 12-month target, down 13% from $156.01, with 21 neutral ratings out of 27, per Nasdaq data, reflecting caution.
Volatility Check: The VIX at 14.49 suggests stability, but a spike to 17-20 could test Palantir's $150 support, with 12.3 million shares traded yesterday above average.

The pullback could be a pause, but macro and valuation risks loom large.

Profit-Taking or Bigger Correction? The Week’s Outlook

Is this a temporary breather or a deeper dive?

Bull Case: A rebound to $165 (5% upside) is possible by Friday, August 22, if $150 holds and AI contracts like the $1.2 billion backlog shine, with a 12-month target of $200 (28% gain) if growth accelerates.
Bear Case: A 5-10% drop to $142-$148 looms if $150 breaks, with $125 as a floor; Citron's $40 target implies a 74% downside if AI demand falters.
Growth Momentum: Q2's $1.04 billion revenue (up 48% YoY) and raised guidance to $4.14-$4.15 billion for 2025 suggest resilience, but H1's 20% U.S. commercial growth slowdown raises doubts.
Catalyst Watch: Jackson Hole Symposium (August 21-23) Fed comments and Q3 guidance previews could sway sentiment, with tariff escalations or profit-taking testing the rally.
Daily Forecast: $152-$160 (Wednesday), $150-$158 (Thursday), $148-$165 (Friday), per analyst trends, with $150 as the pivotal level.
Long-Term View: If revenue hits $5 billion by 2026 and margins rise to 30%, a $250 target (60% upside) is feasible, but a macro downturn could cap gains at $100 (36% downside).

The outlook leans toward consolidation, but risks are real.

Is Palantir Still Your Favorite? Sleeper or Slump?

Palantir's 100%+ year-to-date gain to $158 makes it a favorite for many, but the pullback has sparked debate:

Bull Argument: Its $2.5 billion annual contract value and 104 deals over $1 million highlight long-term strength, with a rebound to $165-$170 possible this week if $150 holds.
Bear Argument: Citron's $40-$50 target and a 95% MIT report on zero AI ROI question its 268x forward P/E, suggesting a bigger correction to $125 if sentiment sours.
Favorite Status: Posts found on X show bulls defending its AI edge, while bears call it an "overvalued trap," reflecting a valuation bubble risk.
Valuation Check: At $40, a 74% drop, it trades at a 20x P/E on $5 billion projected revenue, aligning with traditional software peers like Microsoft (30x).
Long-Term Play: If AI contracts grow to $1.5 billion quarterly by 2026, a $200 target (27% upside) is in sight, but execution risks echo in the current slump.

Palantir remains a favorite for AI believers, but the dip tests loyalty.

Trading Strategies: Navigate the Pullback

Short-Term Plays

Buy the Dip: Buy at $150-$152, target $165-$170, stop at $147. A 9-12% gain if support holds.
Bearish Hedge: Buy puts at $150, target $140, stop at $153. A 6-7% win if correction deepens.
Sector Pivot: Buy Health Care ETF (XLV) at $150, target $155, stop at $148. A 3% gain if rotation continues.
Profit Lock: Sell at $160-$162, target $155-$158, stop at $165. A 2-3% gain if volatility spikes.
Options Play: Buy $165 calls or $140 puts (August expiry) for 150-200% gains on a 5-10% move.

Long-Term Investments

Hold Palantir: Buy at $150-$152, target $200-$250 by 2026, for 27-58% upside if AI growth holds. Stop at $140.
Diversify Up: Buy CVS Health at $65-$67, target $77-$80, for 15-23% upside. Stop at $62.
Value Bet: Buy Pfizer (PFE) at $27-$28, target $35-$38, for 26-36% upside. Stop at $25.
Defensive Hold: Buy PepsiCo (PEP) at $185-$187, target $200-$210, for 7-13% upside. Stop at $180.

Hedge Strategies

VIXY ETF: Buy at $14, target $17, stop at $12, to hedge volatility.
SPY Puts: Use puts at 6,400 for a 5-10% market drop.
Gold (GLD): Buy at $200, target $210, stop at $195, as a buffer.

My Trading Plan: Betting on a Rebound

I’m seizing this dip with a strategic mix. I’ll buy Palantir at $150-$152, targeting $165, with a $147 stop, betting on a rebound. I’ll add CVS at $65-$67, aiming for $75, with a $62 stop, for diversification. I’ll include Pfizer at $27-$28, targeting $32, with a $25 stop, and PepsiCo at $185-$187, targeting $195, with a $180 stop. I’m hedging with VIXY at $14, targeting $16, and holding 20% cash for a drop to $142 or tariff news. I’ll monitor AI contract updates and Fed signals closely.

Key Metrics

The Bigger Picture

Palantir’s six-day plunge to $156.01, down 18% from $190.50, tests investor resolve against a 6,466.58 S&P 500 and $115,000 Bitcoin. A 4-6% rebound to $165 is possible this week if $150 holds, with a long-term $250 target (60% upside) by 2026 if AI growth persists. A 5-10% dip to $142-$148 threatens if $150 breaks, potentially signaling a 20% correction to $125 if macro risks like tariffs (30-35%) or AI skepticism escalate. The 93% YTD gain and $1 billion revenue milestone show strength, but Citron’s $40 target and high P/E (245x) fuel doubt. Buy the dip with VIXY or GLD hedges, and monitor Fed signals. This could be your chance to win big.

Is Palantir’s dip your buy signal or a red flag? Share your view below! 🎁

📢 Like, repost, and follow for daily updates on market trends and stock insights.

📝 Disclaimer: This post is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.

📌@Daily_Discussion @Tiger_comments @TigerStars @TigerEvents @TigerWire @CaptainTiger @MillionaireTiger

Palantir Secures £1.5B UK Deal: Up 134% YTD! Still Room to Run?

UK will significantly increase purchases of Palantir Technologies (PLTR) data analytics software, with the U.K. military committing over $1 billion over five years, extending an earlier deal, according to Bloomberg. Following the news, Palantir shares rose 5.1% to close at $176.97. Year-to-date, the stock is up about 134% in 2025, though it remains below its all-time high of $190 on August 12. 👉 With continued government adoption and long-term contracts, could Palantir sustain its strong 2025 rally, or is a consolidation phase likely?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.